8-K: Kimberly-Clark Recasts 2024 Financials Post IFP Joint Venture

Kimberly-Clark Corporation has recast its 2024 financial statements to reflect the International Family Care and Professional (IFP) segment as discontinued operations following a joint venture agreement with Suzano S.A.

Summary

• Kimberly-Clark Corporation is filing this Current Report on Form 8-K to recast certain financial information and related disclosures included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The recasting is due to the International Family Care and Professional (IFP) Transaction, where Kimberly-Clark announced an agreement with Suzano S.A. on June 5, 2025, to form a joint venture comprising substantially all operations of the former IFP segment.
• Suzano S.A. will acquire a 51% interest in the joint venture for approximately $1.7 billion, subject to closing adjustments, with Kimberly-Clark retaining a 49% equity interest.
• Effective in the second quarter of fiscal 2025, the results of the IFP Business are reported as discontinued operations in the company's condensed consolidated financial statements.
• The company's continuing operations are now organized into two reportable segments: North America (NA) and International Personal Care (IPC).
• The 2024 Transformation Initiative, announced on March 27, 2024, is designed to sharpen strategic focus, optimize margin structure, and wire the organization for growth, with expected completion by the end of 2026.
• Total pre-tax savings from the 2024 Transformation Initiative are expected to be $3.0 billion in gross productivity and $200 million in selling, general and administrative expenses, with total anticipated pre-tax costs of approximately $1.5 billion.
• For the year ended December 31, 2024, total 2024 Transformation Initiative charges were $457 million pre-tax ($339 million after-tax).
• On July 1, 2024, the company completed the sale of its personal protective equipment (PPE) business for $635 million, recognizing a pre-tax gain of $566 million ($453 million after-tax).
• Net sales for continuing operations in 2024 declined 2.0% to $16.805 billion, primarily due to unfavorable currency impacts and divestitures, partially offset by 3.9% organic sales growth.
• Operating profit for continuing operations increased 40.0% to $2.700 billion in 2024.
• Diluted earnings per share from continuing operations increased 48.7% to $6.41 in 2024.
• Income from discontinued operations, net of income taxes, was $386 million in 2024, representing a 26.6% increase from the prior year.

Sentiment

Score: 7

Explanation: The filing details a significant strategic realignment through the IFP joint venture and a major transformation initiative. While 2024 net sales declined, adjusted operating profit and EPS showed healthy growth. The strategic moves, including the PPE business sale, are positive for portfolio optimization, but the transformation costs and ongoing market volatility present challenges. The recasting itself is a neutral event, but the underlying strategic shifts are generally positive for long-term focus.

Positives

• Formation of a joint venture for the IFP Business with Suzano S.A., selling a 51% interest for approximately $1.7 billion, while retaining a 49% equity interest, indicating a strategic portfolio optimization.
• The IFP Transaction represents a strategic shift expected to have a major effect on operations and financial results, allowing for a more focused business.
• The 2024 Transformation Initiative aims for significant pre-tax savings of $3.0 billion in gross productivity and $200 million in selling, general and administrative expenses by the end of 2026.
• The sale of the PPE business for $635 million resulted in a substantial pre-tax gain of $566 million ($453 million after-tax) in 2024.
• Organic sales growth for continuing operations was 3.9% in 2024, driven by a 2.7% increase in price, coupled with gains in volume and mix.
• Operating profit for continuing operations increased 40.0% to $2.700 billion in 2024.
• Diluted earnings per share from continuing operations increased 48.7% to $6.41 in 2024.
• Adjusted operating profit for continuing operations increased 7.3% to $2.727 billion in 2024, excluding certain one-time items.
• Adjusted earnings per share for continuing operations increased 8.6% to $6.16 in 2024.
• Income from discontinued operations, net of income taxes, increased 26.6% to $386 million in 2024, primarily due to gross productivity savings.
• North America segment operating profit increased 1.1% to $2.542 billion in 2024, primarily due to gross productivity savings and volume growth.
• International Personal Care segment operating profit increased 22.7% to $826 million in 2024, driven by favorable pricing net of inflation and gross productivity savings.

Negatives

• Net sales for continuing operations declined 2.0% in 2024, primarily due to unfavorable currency impacts and divestitures and business exits.
• The 2024 Transformation Initiative is expected to incur total pre-tax costs of approximately $1.5 billion, with cash costs expected to be approximately half of that amount.
• Operating profit in 2024 included charges of $456 million related to the 2024 Transformation Initiative and $136 million from the impairment of intangible assets and litigation.
• Cash provided by operations decreased to $3.2 billion in 2024 from $3.5 billion in 2023, due to changes in working capital and cash payments for the 2024 Transformation Initiative.
• Cash used for financing increased to $3.2 billion in 2024 from $2.4 billion in 2023, primarily due to increased share repurchases, debt repayments, and dividends paid.
• Adjusted operating results were partially offset by unfavorable currency impacts, primarily due to hyperinflationary economies, and higher marketing, research, and general expenses in 2024.
• Birth rate declines in key countries, including China, South Korea, and the U.S., have pressured category volume growth rates for baby and child care products.
• Increased private label market share in the tissue category could reduce net sales of higher-margin products and negatively impact profitability.
• Net input costs are expected to be inflationary in 2025, including the impact from currency on non-U.S. operations.
• Volatility in global consumer demand, commodity costs, and foreign currency exchange rates increased significantly over the past few years and is expected to continue in the near term.
• Unrealized currency translation adjustments resulted in a loss of $408 million in 2024, contributing to a total other comprehensive income (loss) of -$196 million.

Risks

• Risks and uncertainties around the pending IFP Transaction, including delays or failure to complete the proposed transaction, the incurrence of significant transaction and separation costs, adverse market reactions, regulatory or legal challenges, and operational disruptions.
• Risks that the company is not able to realize the anticipated benefits of the 2024 Transformation Initiative, including risks related to disruptions to business or operations or related to any delays in implementation.
• Impact of the war in Ukraine, including responses of consumers, customers, and suppliers, and sanctions issued by the U.S., the European Union, Russia, or other countries, potentially affecting operations in Russia (which represented approximately 1% to 2% of net global sales, operating profit, and total assets).
• Government trade or similar regulatory actions (including current and potential trade and tariff actions) affecting countries where the company operates, with resulting negative impacts on supply chain, commodity costs, and consumer spending.
• Pandemics, epidemics, fluctuations in foreign currency exchange rates, and the prices and availability of raw materials.
• Supply chain disruptions, disruptions in the capital and credit markets, and counterparty defaults (including customers, suppliers, and financial institutions).
• Failure to realize the expected benefits or synergies from acquisition and disposition activity.
• Impairment of goodwill and intangible assets and projections of operating results affecting impairment testing.
• Changes in customer preferences, severe weather conditions, regional instabilities and hostilities (including the war in Israel).
• Potential competitive pressures on selling prices for products and energy costs.
• General economic and political conditions globally and in the markets in which the company does business, as well as the ability to maintain key customer relationships.
• Climate change risks, including transition risks (increased costs of carbon emission, compliance, raw materials, shifts in customer/consumer values, legal, regulatory, and technological risks) and physical risks (direct damage to assets or supply chain disruption caused by severe weather events).
• Uncertainties related to deferred income taxes and potential assessments, including valuation allowances on deferred tax assets, undistributed earnings of subsidiaries outside the U.S., and uncertain tax positions.
• Ongoing legal proceedings, such as those related to the former health care business (Avanos Medical, Inc.) concerning allegations of potential criminal and civil violations, and environmental protection laws and regulations.
• A dispute with the Brazilian tax authority regarding goodwill amortization benefits (approximately $40 million in proposed tax and penalty adjustments as of December 31, 2024), currently in the judicial phase with an appeal pending.
• U.S. Internal Revenue Service (IRS) adjustments for 2017 and 2018 increasing the one-time transition tax on certain undistributed foreign earnings, and proposed adjustments for 2019 and 2020 increasing U.S. income tax on distributions from minority-owned foreign affiliates.

Future Outlook

Kimberly-Clark expects capital spending to be approximately $1.0 billion to $1.2 billion in 2025, including incremental spending from the 2024 Transformation Initiative. Net input costs are expected to be inflationary in 2025, including currency impacts on non-U.S. operations. The IFP Transaction is expected to close in mid-2026, pending consultation requirements and customary regulatory approvals. The 2024 Transformation Initiative is expected to be completed by the end of 2026, aiming to drive durable, long-term growth and reduce structural costs. The company will continue to monitor and evaluate new legislation and guidance regarding the Pillar 2 tax framework and the impact of climate-related disclosure rules.

Management Comments

• We are a global company focused on delivering essential products and solutions that solve unmet consumer needs and provide Better Care for a Better World.
• We will continue executing our Powering Care strategy and its three synergistic, strategic pillars: accelerate pioneering innovation, optimize our margin structure, and wire our organization for growth.
• Our capital allocation approach prioritizes capital investments to drive durable growth in our business, a strong and growing dividend, value accretive acquisitions that can enhance our portfolio, and allocation of excess cash flow to share repurchases.
• We believe our Powering Care strategy, sharpened growth focus, sustainability initiatives, innovation pipeline and continued investment in e-commerce capabilities underpinned by our commitment to delivering Better Care for a Better World make us well positioned relative to these changing external dynamics.
• We believe that our ability to generate cash from operations and our capacity to issue short-term and long-term debt are adequate to fund working capital, obligations related to our 2024 Transformation Initiative, capital spending, pension contributions, share repurchases, dividends and other needs for the foreseeable future.

Industry Context

The recasting of financials and the IFP joint venture reflect a broader industry trend of consumer goods companies optimizing their portfolios by divesting non-core assets or forming strategic partnerships to focus on higher-growth or higher-margin segments. The 2024 Transformation Initiative aligns with industry efforts to streamline supply chains, enhance productivity, and adapt to evolving consumer preferences and e-commerce growth. The company's focus on innovation and sustainability also mirrors key competitive drivers in the personal and family care sectors, aiming to maintain competitiveness in a highly dynamic global marketplace characterized by intense competition and evolving consumer demands.

Corporate Governance

Legal Proceedings

• Routine involvement in legal proceedings, claims, disputes, tax matters, regulatory matters, and governmental inspections or investigations arising in the ordinary course of business.
• Party to certain legal proceedings relating to the former health care business, Avanos Medical, Inc., including a qui tam matter and subpoenas from the United States Department of Justice concerning allegations of potential criminal and civil violations of federal laws related to the manufacturing, marketing, and sale of surgical gowns.
• Named a potentially responsible party under the provisions of the U.S. federal Comprehensive Environmental Response, Compensation and Liability Act, or analogous state statutes, at a number of sites where hazardous substances are present.
• Dispute with the Brazilian tax authority (Secretaria da Receita Federal do Brasil RFB) regarding proposed adjustments that effectively eliminate goodwill amortization benefits related to prior acquisitions in Brazil, with approximately $40 million in proposed tax and penalty adjustments as of December 31, 2024, currently in the judicial phase with an appeal pending.
• U.S. Internal Revenue Service (IRS) issued an adjustment for the taxable years ended December 31, 2017 and 2018, that would increase the amount of the one-time transition tax on certain undistributed earnings of foreign subsidiaries.
• U.S. IRS proposed an adjustment for the taxable years ended December 31, 2019 and 2020, that would increase the amount of U.S. income tax on distributions made by minority-owned foreign affiliates.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through portfolio optimization and cost savings from the 2024 Transformation Initiative; impact from share repurchases and dividends; risks from market volatility and legal proceedings.
• Employees: Workforce reductions expected in the range of 4% to 5% due to the 2024 Transformation Initiative, impacting all major geographies.
• Customers: Potential for enhanced product innovation and improved offerings through the Powering Care strategy; changes in product availability or branding due to divestitures and segment realignments.
• Suppliers: Potential for changes in supply chain relationships due to network optimization and value stream simplification under the transformation initiative; participation in supplier finance program.
• Creditors: Impact from debt repayments and new debt issuances; maintenance of revolving credit facilities for liquidity and commercial paper program support.

Next Steps

• Closing of the IFP Transaction with Suzano S.A. expected in mid-2026, pending consultation requirements and customary regulatory approvals.
• Completion of the 2024 Transformation Initiative by the end of 2026.
• Expected capital spending of approximately $1.0 billion to $1.2 billion in 2025, including incremental spending from the 2024 Transformation Initiative.
• Expected contribution of approximately $15 million to defined benefit pension plans in 2025.
• Monitoring and evaluating new legislation and guidance regarding the Pillar 2 tax framework.
• Monitoring litigation progress for possible impacts on climate-related disclosure requirements under SEC Release No. 33-11275.
• Evaluating the impact of ASU No. 2024-03 on consolidated financial statements and related disclosures.

Key Dates

Recommendation

The filing outlines a significant strategic pivot with the IFP joint venture and a comprehensive transformation initiative. While the recast 2024 financials show strong adjusted operating profit and EPS growth, the overall net sales decline and substantial costs associated with the transformation introduce near-term uncertainties. The long-term benefits of portfolio optimization and cost savings are promising, but execution risks and ongoing market volatility warrant a 'hold' position until the benefits of these strategic changes become more clearly realized and the associated costs are absorbed.

Keywords

Kimberly-Clark, KMB, SEC Filing, 8-K, Financial Recast, Discontinued Operations, Joint Venture, Suzano S.A., IFP Business, 2024 Transformation Initiative, PPE Business Sale, Organic Sales Growth, Operating Profit, EPS, Consumer Goods, Personal Care, Family Care, Corporate Governance, Risk Factors, Financial Reporting